Leveraging the epigenome's power, we are forging ahead to craft the next era of genetic therapies.
We utilize artificial intelligence models to strategically choose the interventions we investigate.
We leverage our understanding of reprogramming factor biology and the outcomes of previous experiments to guide the selection of subsequent experiments.
We target age-related diseases as a strategy to address the major health concern of healthy ageing and to extend the healthspan.
Epigenetic interventions are the promising avenue for extending healthspan and potentially lifespan.
Epigenome editing stands as a groundbreaking pillar of genetic medicine, made possible by cutting-edge advancements in understanding gene regulation. This technology grants unprecedented precision in controlling gene activity — whether it's activation, suppression, or fine-tuning—to combat cellular dysfunction and diseases.
We are now poised to tackle thousands of both rare and common diseases lacking curative treatments. In this pursuit, we are steadfastly working towards our ultimate aspiration: unleashing the full potential of longevity medicine and extending the healthspan.
